Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia.
CONCLUSIONS: Currently, there is no high-quality evidence to support or challenge the continued use of hydroxyurea for managing people with transfusion-dependent β-thalassaemia. Multicentre, randomised controlled trials (compared to placebo or other available treatment, i.e. blood transfusion and iron chelation) are needed in order to assess the efficacy and safety of hydroxyurea for reducing the need for blood transfusion, for maintaining or improving mean haemoglobin levels, as well as for determining its cost-effectiveness.
PMID: 30882896 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Ansari SH, Lassi ZS, Khowaja SM, Adil SO, Shamsi TS Tags: Cochrane Database Syst Rev Source Type: research
More News: Anemia | Blood Transusion | Conferences | Cystic Fibrosis | Databases & Libraries | General Medicine | Genetics | Iron | Sickle Cell Anemia | Study